World Data on Ambroxol for Patients With GD and GBA Related PD

Plain-language summary

This study aims to gather worldwide data on the use of Ambroxol in patients with Gaucher disease or GBA-related Parkinson's disease. It is open to people with Gaucher disease type 1, 2, or 3, or with GBA-related Parkinson's disease. It is a non-phase study and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Shaare Zedek Medical Center

Start date

5/6/2020

Estimated completion

11/30/2030

Countries

Israel

Related genes

Locations

• Jerusalem, Israel
• Jerusalem, Israel
• Jerusalem, Israel

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* patients with Gaucher disease type 1,2 or 3(a,b,c).
* patients with GBA-related Parkinson disease.

Exclusion Criteria:

* None.